GentaGel-LR was founded in late 2021 by Dr. Ariel Orbach, Mr. Eli Lerner, and Professor Abraham J. Domb. The company is based on a ground-breaking drug delivery technology invented by Prof. Domb, for the in-situ sustained release of antibiotics for the treatment and prevention of surgical site infections.
GentaGel offers a local slow-release antibiotic treatment which is injected and continuously releases antibiotics (e.g., Gentamicin) for up to 60 days. The antibiotic is not detectable in circulation but achieves sufficient therapeutic concentrations in the administered area. Thus, GentaGel provides an effective antibiotic treatment while avoiding systemic side-effects and expensive cost-of-care.
The Company is entering the clinical stage with a FIH Study to be conducted at the Sheba Medical Center, Israel.
Company Details
- Employees
- 1
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://gentagel-lr.com/
Gentagel-Lr Questions
Gentagel-Lr's website is https://gentagel-lr.com/
Gentagel-Lr's LinkedIn profile is https://www.linkedin.com/company/gentagel-lr
Gentagel-Lr has
1 employees.
View email and phone details for 1
employees at Gentagel-Lr.
Gentagel-Lr's industry is
Biotechnology Research
Gentagel-Lr's top competitors are
Cardea Sciences,
Snipe Medical,
Technopulm,
Snibe,
Caleetech,
Sorlis,
Becapio,
Luseed Vascular,
Sherman Diagnostics,
Predicta Med.
Gentagel-Lr's categories are Biotechnology Research
Gentagel-Lr's founding year is 2021
